Cytek Biosciences (CTKB) IPO Opens 24% Higher

Today's IPO for Cytek Biosciences, Inc. (Nasdaq: CTKB) opened for trading at $21.10 after pricing 6,749,330 shares of its common stock at a price to the public of $17.00 per share.

Morgan Stanley, Goldman Sachs & Co. LLC, Piper Sandler & Co. and Cowen are acting as joint book running managers for the offering.

Cytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights systems, its cell sorter, the Aurora CS, and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe.

Other than Cytek’s Northern Lights CLC system, which is available for clinical use in China and the European Union, Cytek’s products are for research use only – not for use in diagnostic procedures or for clinical purposes.

Cytek, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc.

You May Also Be Interested In

• Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
• Ibotta (IBTA) Announces 6.56M Share IPO at $76-$84/sh
• Lithium Americas Corp (LAC) Prices 55M Share Offering at $5/sh